Memorial Sloan Kettering and Cell describe a CAR T approach targeting uPAR, a protein on cancer cells and supportive tumor microenvironment cells, aiming to widen CAR T applicability beyond single tumor antigens.
MSK researchers and their collaborators have developed a new type of CAR T cell designed to target a cell surface protein called uPAR, which is found on cancer cells as well as supportive cells in the tumor microenvironment.
Now online! A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare